The deadly clash of 10 people from Miami on the high seas near Cuba this week turns out to be highly symbolic. >> Now to our other major story tonight, Cuba's shootown of two small planes piloted by Cuban exiles off of Venice coast. >> Almost 30 years to the day after Soviet made Cuban MIG fighter jets shot down two unarmed civilian Cessnes approaching Cuba piloted by Cuban Americans calling themselves the brothers to the rescue.The order to shoot down their plane came, NBC was told, from Fidel Castro himse ...

A number of key European credit indicators deteriorated on Monday, with an index of regional junk corporate credit hitting its highest yield since November on investor jitters over conflict in the Mi... ...

NEW YORK--(BUSINESS WIRE)--MSCI Inc. ("MSCI†or the "Company†) (NYSE: MSCI) announced today that Luke Flemmer, Head of Private Assets, will be participating in a fireside chat at the RBC Capital Markets Global Financial Institutions Conference on Tuesday, March 10, 2026 at 2:40PM Eastern Time. A live webcast and replay of this event will be available on the events and presentations section of MSCI's Investor Relations homepage at https://ir.msci.com/events-and-presentations. About MSCI Inc. MSC. ...

Abel also made it clear that he isn’t auditioning for Wall Street’s favorite role: “new guy who returns a ton of cash.” On dividends, the policy remains the Berkshire catechism — that the company won’t pay cash dividends as long as “more than one dollar of market value for shareholders is reasonably likely to be created by each dollar of retained earnings.” This isn’t a story about a new quarterback calling flashy audibles. It’s about running the same offense until the defense gets tired.In his first letter ...

Indeed, it is madnessStephen Miller (@StephenM):If an illegal alien lives in a sanctuary jurisdiction they will be allowed by Democrat leaders to commit infinity crimes. ...

Your daily essential crypto market analysis:https://t.co/UtmumnX1PN ...

War is reshaping markets. Bitcoin could be the beneficiary.Crypto Daybook Americas, presented by @Fidelity. https://t.co/yDmFDz094A ...

Recorlev's growth was driven by continued expansion of the patient base, ending the year at approximately 700 patients nearly doubling the number of patients on therapy from a year-end 2024. This growth reflects expanding prescriber awareness in a very dynamic market coupled with increasing confidence in Recorlev's differentiated clinical profile. Turning to this year. In January, we nearly doubled our Recorlev commercial team significantly expanding our sales and patient support organizations to increase t ...

Editas Medicine FY Conference Summary Company Overview - **Company**: Editas Medicine (NasdaqGS:EDIT) - **Stage**: Preclinical stage company - **Lead Asset**: EDIT-401, targeting hyperlipidemia with a potential 90% reduction in LDL cholesterol [2][10] Core Strengths - **Mechanistic Approach**: Focused on CRISPR therapeutics to increase disease-mitigating proteins by editing non-coding DNA [2][4] - **In Vivo Delivery**: Simplifies treatment for patients and healthcare systems, enhancing the value proposition for payers [3][5] - **Funding**: Financially supported until Q3 2027, allowing for continued development of EDIT-401 [4][54] Key Challenges - **CRISPR Space**: General challenges in the CRISPR field, although recent positive developments in Intellia's TTR program provide some optimism [3][4] Differentiation in Gene Editing - **Editing Strategy**: Unique approach using CRISPR to augment biology rather than just knockdown, targeting non-coding DNA to regulate protein expression [8][9] - **Effect Size**: EDIT-401 shows a 90% reduction in LDL cholesterol in non-human primates, significantly outperforming existing therapies like PCSK9 antagonism [10][11] Clinical Development - **Proof of Concept Timeline**: Human proof of concept data expected by the end of 2026, with filings for IND or CTA anticipated mid-year [27][28] - **Target Population**: Focus on heterozygous familial hypercholesterolemia (HEFH) patients and those with established cardiovascular disease [28][33] Market Opportunity - **Patient Population**: Approximately 10 million patients in the U.S. with high cholesterol not reaching treatment goals, representing a significant market [33][34] - **Competitive Edge**: Aiming for a 70%-90% reduction in LDL cholesterol, which aligns with evolving treatment goals in Europe [34][35] Future Pipeline - **Additional Programs**: Continued optimization of hematopoietic stem cell (HSC) programs for sickle cell disease and thalassemia, alongside liver-targeted therapies [39][40] Intellectual Property and Manufacturing - **Patent Dispute**: Ongoing legal matters regarding foundational IP, with optimism for a favorable outcome [45][46] - **Manufacturing Strategy**: Outsourced model for LNP manufacturing, leveraging expertise gained during the pandemic to control costs [48][49] Financial Position - **Cash Balance**: Ended 2025 with $65 million, with a runway extending into Q3 2027 [54] Conclusion - **Transformative Potential**: EDIT-401 represents a significant advancement in CRISPR technology, with the potential to change treatment paradigms for hyperlipidemia and improve patient outcomes [56]

RadNet (NasdaqGM:RDNT) Q4 2025 Earnings call March 02, 2026 10:30 AM ET Company ParticipantsAndrew Mok - DirectorHoward Berger - President and CEOKees Wesdorp - President and CEO of Digital HealthLarry Solow - Managing DirectorMark Stolper - EVP and CFOSham Sokka - COO and CTO of Digital HealthYuan Zhi - Managing DirectorConference Call ParticipantsBrian Tanquilut - Senior Healthcare Services AnalystDavid MacDonald - Managing Director and Senior Equity Research AnalystJim Sidoti - AnalystMatthew Gillmor - D ...